Le Lézard
Classified in: Health
Subject: FDA

Flashback Technologies Announces U.S. FDA Clearance For The CipherOx® CRI M1 Compensatory Reserve Index (CRItm) Monitor To Accurately Detect And Trend Acute Blood Loss


LOUISVILLE, Colo., July 26, 2018 /PRNewswire/ -- Flashback Technologies, Inc. has been granted 510(k) clearance by the U.S. FDA for the CipherOx® CRI M1 monitor, a handheld device that noninvasively calculates and displays heart rate, SpO2 and the Compensatory Reserve Index (CRI). CRI is a breakthrough hemodynamic parameter that provides real-time, noninvasive indication of changes in intravascular volume relative to the individual patient's response to blood loss. The M1 is Flashback's first commercial CRI product to market.  Sales of the M1 will begin in the coming weeks.

Steve Moulton, MD, Co-Founder at Flashback and Director, Trauma and Burn Services at Children's Hospital Colorado, stated "The M1 is a cutting edge medical device designed to detect and continuously monitor acute blood loss in the field and in hospital settings.  It will enable healthcare providers to identify and respond to the needs of acutely bleeding patients much earlier, when their physiology is less complex and more likely to respond to therapy."

CRI was initially developed with support from the US Army to meet their need for noninvasive monitoring of acute blood loss. It is the first in a new FDA category of "adjunctive cardiovascular status indicators" and represents a new vital sign in patient monitoring. CRI provides an indication of an individual patient's ability to compensate for intravascular fluid loss (e.g. blood loss) on a scale ranging from 1 (replete intravascular volume) to 0 (high risk of hemodynamic decompensation). It is a proprietary technology, developed using Flashback's advanced data analytics platform CipherSensortm. To date there are more than 20 published clinical and laboratory studies establishing the effectiveness of CRI in detecting and monitoring blood loss.

"We are excited to put CRI technology in the hands of medics and physicians, where it will really make a difference by helping to detect and manage patients experiencing blood loss," commented Greg Grudic, PhD, President and Co-Founder at Flashback. 

The CipherOx® CRI M1 displays CRI as a "fuel gauge" that goes down or up, depending on whether the patient continues to lose volume (bleed) or gain volume (active fluid resuscitation).  The screen also displays the instantaneous CRI value, a 20-minute trend graph, HR and SpO2 values. The device is battery powered and intended for use in pre-hospital and hospital settings.

About Flashback

Flashback Technologies, Inc. uses the power of data analytics for good, by applying their patented CipherSensortm technology to develop powerful precision monitors for the medical marketplace. Flashback is located in Louisville, CO, and collaborates closely with leading medical research institutions, including various groups within the U.S. Department of Defense, Children's Hospital Colorado and the University of Colorado, Anschutz Medical Campus, Aurora, CO.

For additional information visit www.flashbacktechnologies.com or contact [email protected].

 

SOURCE Flashback Technologies, Inc.


These press releases may also interest you

at 07:35
Cybin Inc. (Cboe CA:CYBN) ("Cybin" or the "Company"), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative next-generation psychedelic-based treatment options, today announced...

at 07:30
MedBright AI Investments Inc. (the "Company" or "MedBright") today announced that Dermatology Institute & Skin Care Center (DISCC) has signed a 3 year contract to use the MedMatrix AI Platform, including all 5 product modules in their single clinic...

at 07:30
UniDoc Health Corp. (FRA: L7T) ("UniDoc," or the "Company"), an innovator in the eHealth sector, proudly announces the deployment of an H3 Health Cube to Ketchikan, Alaska. This initiative, in collaboration with Planet Defense, LLC, marks a...

at 07:30
Virax Biolabs Group Limited ("Virax" or the "Company"), an innovative biotechnology company focused on the detection of immune responses and diagnosis of viral diseases, announced today that it will be hosting a booth at the European Society of...

at 07:25
Cardiawave SA, a French Medtech company that has developed an innovative Non-Invasive Ultrasound Therapy (NIUT) device for the treatment of severe symptomatic calcific aortic stenosis, is delighted to announce the appointment of Olivier Pierron as...

at 07:15
Arch Biopartners Inc., ("Arch" or the "Company") , announced today that a research team from St. Michael's Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac...



News published on and distributed by: